Arachidonic acid induced platelet aggregation and thromboxane formation is inhibited by OKY-1581.
Addition of arachidonic acid (AA) to human platelet rich plasma caused a reversible platelet aggregation and a concomitant formation of thromboxane B2 (TXB2). Both AA-induced platelet aggregation and TXB2 formation were inhibited by OKY-1581 and the amounts of PGE2 and PGF2 alpha formed were correspondingly increased. The formation of 6-keto-PGF1 alpha was smaller and was increased only slightly by OKY-1581. ADP-induced platelet aggregation did not result in the formation of TXB2 and it was inhibited only slightly by OKY-1581. When ADP was added to platelet rich plasma six minutes after the addition of AA, the ADP-induced aggregation was greatly decreased in the presence and absence of OKY-1581. The present study indicates that the AA-induced platelet aggregation is inhibited by OKY-1581 and that OKY-1581 is a specific inhibitor of thromboxane synthesis in platelet rich human plasma.
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000179:Acrylates / Q000494:pharmacology*; D000244:Adenosine Diphosphate / Q000494:pharmacology; D000328:Adult; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000494:pharmacology*; D015237:Dinoprost; D015232:Dinoprostone; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D008689:Methacrylates / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects*; D011458:Prostaglandins E / Q000097:blood; D011460:Prostaglandins F / Q000097:blood; D013929:Thromboxane B2 / Q000097:blood*; D013931:Thromboxanes / Q000097:blood*
D000179:Acrylates; D001095:Arachidonic Acids; D008689:Methacrylates; D011458:Prostaglandins E; D011460:Prostaglandins F; D013931:Thromboxanes; D016718:Arachidonic Acid; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D000244:Adenosine Diphosphate; C031517:2-methyl-3-(4-(3-pyridinylmethyl)phenyl)-2-propenoic acid; D015237:Dinoprost; D015232:Dinoprostone